Tag Archives: CADTH
CASGEVY: Rethinking Drug Costs Through the Lens of Public Access
Maria Klimenko considers the extent to which the price of innovative treatments like CASGEVY, a type of gene therapy, should reflect not just the cost of development, but also their broader societal impact — and the public healthcare system’s ability to provide equitable access.
Impact Ethics 